Anti-Kaposi’s Sarcoma and Antiangiogenic Activities of Sulfated Dextrins | Zendy

Mark Thornton | Zendy; Laura R. Barkley | Zendy; Justin C. Mason | Zendy; Sunil Shaunak | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Anti-Kaposi’s Sarcoma and Antiangiogenic Activities of Sulfated Dextrins

Author(s) -

Mark Thornton,

Laura R. Barkley,

Justin C. Mason,

Sunil Shaunak

Publication year - 1999

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.43.10.2528

Subject(s) - dextrin , umbilical vein , angiogenesis , sulfation , sarcoma , in vitro , chemistry , lymphatic endothelium , cancer research , protamine sulfate , biochemistry , immunology , lymphatic system , medicine , pathology , heparin , starch , protamine

Delivery of the sulfated polysaccharide dextrin 2-sulfate by the intraperitoneal route to the lymphatic circulation resulted in a clinically significant improvement in Kaposi's sarcoma in three patients. Our in vitro studies show that although sulfated dextrins do not interfere with the growth of isolated human umbilical vein endothelial cells, they do inhibit the morphological differentiation of endothelial cells into tubes as well as reduce new vessel formation in a placental angiogenesis assay. The antiangiogenic effect of dextrin 6-sulfate is greater than that of dextrin 2-sulfate and is independent of their anti-human immunodeficiency virus type 1 activities.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research